J&J | The Business Standard
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
WEDNESDAY, MAY 25, 2022
WEDNESDAY, MAY 25, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা

J&J

A healthcare worker administers a dose of the Pfizer coronavirus disease (Covid-19) vaccine to a teenager, amidst the spread of the SARS-CoV-2 variant Omicron, in Johannesburg, South Africa, December 9, 2021.  Photo :Reuters
Coronavirus chronicle

No Omicron deaths in J&J vaccine study in South Africa, scientist says

The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019/Reuters
Global Economy

Healthcare giant Johnson & Johnson to split into two companies

Johnson & Johnson company offices are shown in Irvine, California, U.S., October 14, 2020. REUTERS/Mike Blake/File Photo
Coronavirus chronicle

US brokers J&J-COVAX deal to send vaccines to conflict zones -Blinken

J&J settles most Risperdal lawsuits, with $800 million in expenses
USA

J&J settles most Risperdal lawsuits, with $800 million in expenses

FILE PHOTO: A healthcare worker holds a vial of the Moderna COVID-19 vaccine at a pop-up vaccination site operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in Manhattan in New York City, New York, U.S., January 29, 2021. REUTERS/Mike Segar/File Photo
Coronavirus chronicle

US FDA clears Moderna, J&J Covid-19 boosters, backs use of different vaccine for boost

Syringes filled with a doses of Pfizer's coronavirus disease (COVID-19) vaccine are seen at a pop-up community vaccination center at the Gateway World Christian Center in Valley Stream, New York, US, February 23, 2021. REUTERS/Brendan McDermid
Coronavirus chronicle

Moderna or Pfizer booster works better for people vaccinated with J&J: study

The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019/Reuters
USA

Six US states do not join $26 billion opioid settlements with distributors, J&J

Empty vials of Johnson & Johnson's coronavirus disease (Covid-19) vaccine are seen on a table at a vaccination centre in Ronda, Spain, April 23, 2021. Photo :Reuters
Coronavirus chronicle

J&J says US FDA agrees to extend shelf life of its Covid-19 vaccine

A bottle of Johnson and Johnson Baby Powder is seen in a photo illustration taken in New York, February 24, 2016. Photo :Reuters
World+Biz

J&J exploring putting talc liabilities into bankruptcy

Johnson & Johnson company offices are shown in Irvine, California, U.S., October 14, 2020. REUTERS/Mike Blake/File Photo
World+Biz

J&J reaches $230 mln opioid settlement with New York state

Poor countries deserve a shot. Photo: Bloomberg
Panorama

The real vaccine crisis isn’t about J&J or AstraZeneca

Vials of Johnson & Johnson's Janssen coronavirus disease (COVID-19) vaccine candidate are seen in an undated photograph. Johnson & Johnson/Handout via REUTERS.
Coronavirus chronicle

J&J to deliver Covid vaccine to Europe from April 19

Vials with a sticker reading, "Covid-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

US to distribute 4 million J&J Covid vaccines by Tuesday

  • Show More
The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab